Treatment of HIV: Agents 1999 and beyond nucleoside and non nucleoside reverse transcriptase inhibitors
Ramírez-Ronda, C.H.; Ramírez-Ramírez, C.R.
Boletin de la Asociacion Medica de Puerto Rico 91(1-6): 51-59
1999
ISSN/ISBN: 0004-4849 Document Number: 703021
Nucleoside analogue reverse transcriptase inhibitors (nRTIs) remain a mainstay of antiretroviral chemotherapy. At this writing, five members of this class of drugs have been approved by the FDA, and a six (abacavir, 1592U89) is likely to be approved within the next few months. The mechanism of action common to this class of agents involves the incorporation of triphosphate metabolites into viral DNA during the process of reverse transcription.
Document emailed within 1 workday
Related Documents
Engchanil, C.; Kosalaraksa, P.; Lulitanond, V.; Lumbiganon, P.; Chantratita, W. 2006: Multi-drug resistant HIV-1 reverse transcriptase genotype in children treated with dual nucleoside reverse transcriptase inhibitors (NRTIs) Journal of the Medical Association of Thailand 89(10): 1713-1720Brzezińska, E.; Glinka, R. 2002: Search for new non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-1 RT) Acta Poloniae Pharmaceutica 59(5): 379-386
2000: Non-nucleoside reverse transcriptase inhibitors. First line therapy MMW Fortschritte der Medizin 142(3 Suppl): 34-35
Tarby, C.M. 2004: Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors Current Topics in Medicinal Chemistry 4(10): 1045-1057
Wainberg, M.A.; Sawyer, J.P.C.; Montaner, J.S.G.; Murphy, R.L.; Kuritzkes, D.R.; Raffi, F. 2005: Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection Antiviral Therapy 10(1): 13-28
Stankov, M.V.; Lücke, T.; Das, A.M.; Schmidt, R.E.; Behrens, G.M.N. 2007: Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors Antiviral Therapy 12(2): 205-216
Vemula, S.; Kerr, S.; Pancharoen, C.; Siripong, A.; Kosalaraksa, P.; Engchanil, C.; Chuamchaitrakool, A.; Intasan, J.; Lumbiganond, P.; Phanuphak, P.; Ananworanich, J. 2007: Incidence and risk factors for non-nucleoside reverse transcriptase inhibitors (NNRTI)-related rash in Thai children with HIV infection Journal of the Medical Association of Thailand 90(11): 2437-2441
Flandre, P.; Descamps, D.; Joly, V.; Meiffrédy, V.; Tamalet, C.; Izopet, J.; Aboulker, J-Pierre.; Brun-Vézinet, Fçoise. 2003: Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received Antiviral Therapy 8(1): 65-72
Ramachandran, G.; Kumar, A.K.Hemanth.; Ponnuraja, C.; Ramesh, K.; Rajesh, L.; Chandrasekharan, C.; Swaminathan, S. 2013: Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients Indian Journal of Medical Research 138(6): 955-961
Arenas-Pinto, A.; Bhaskaran, K.; Dunn, D.; Weller, I.V.D. 2008: The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial Antiviral Therapy 13(2): 289-295
Sachdeva, R.K.; Wanchu, A.; Bagga, R.; Malla, N.; Sharma, M. 2010: Effect of non-nucleoside reverse transcriptase inhibitors on cytokine, chemokine, and immunoglobulin profiles in serum and genital secretions of HIV-infected women Journal of Interferon and Cytokine Research: the Official Journal of the International Society for Interferon and Cytokine Research 30(5): 299-310
Mankhatitham, W.; Luaengniyomkul, A.; Manosuthi, W. 2012: Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy Journal of the Medical Association of Thailand 95(2): 163-169
Song, L.; Ding, S.; Ge, Z.; Zhu, X.; Qiu, C.; Wang, Y.; Lai, E.; Yang, W.; Sun, Y.; Chow, S.A.; Yu, L. 2018: Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells British Journal of Pharmacology 175(8): 1241-1259
Ripamonti, D.; Maggiolo, F. 2008: Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection Current Opinion in Investigational Drugs 9(8): 899-912
Mesplet, N.; Morin, P.; François, C.; Agrofoglio, L.A. 2001: Simultaneous quantitation of nucleoside HIV-1 reverse transcriptase inhibitors by short-end injection capillary electrochromatography on a beta-cyclodextrin-bonded silica stationary phase Journal of Chromatography A 927(1-2): 161-168
Berezovskaia, I.V.; Chudinov, M.V. 2005: Ester derivatives of nucleoside inhibitors of reverse transcriptase: I. Molecular transport systems for 3'-azido-3'-deoxythymidine and 2',3'-didehydro-3'-deoxythymidine Bioorganicheskaia Khimiia 31(4): 339-356
Reinis, M.; Vandasová, J.; Stanková, M.; Linka, M.; Brůcková, M. 2001: Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing Acta Virologica 45(5-6): 279-286
Berezovskaia, I.V.; Chudinov, M.V. 2005: Ester derivatives of nucleoside inhibitors of reverse transcriptase: II. Molecular systems for combined therapy with 3'-azido-3'-deoxythymidine and 2',3'-didehydro-3'-deoxythymidine Bioorganicheskaia Khimiia 31(5): 451-465
Russo, G.; Paganotti, G.M.; Soeria-Atmadja, S.; Haverkamp, M.; Ramogola-Masire, D.; Vullo, V.; Gustafsson, L.L. 2016: Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments Infection Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 37: 192-207
Germanaud, D.; Derache, A.; Traore, M.; Madec, Y.; Toure, S.; Dicko, F.; Coulibaly, H.; Traore, M.; Sylla, M.; Calvez, V.; Marcelin, A.-G. 2010: Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali Journal of Antimicrobial ChemoTherapy 65(1): 118-124